Related Experiment Video
Updated: Aug 12, 2026
10:50
Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010
Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants
1Center for AIDS Research, Stanford University, Stanford, California 94305-5107, USA. euny@stanford.edu
AIDS Research and Human Retroviruses
|April 3, 2001
Summary
3'-fluoro-3'-deoxythymidine (FLT) shows potent antiviral activity against multidrug-resistant HIV-1 strains. This nucleoside reverse transcriptase inhibitor demonstrates efficacy where other drugs fail, suggesting potential for salvage therapy.
Area of Science:
- Virology
- Pharmacology
- Molecular Biology
Background:
- Human immunodeficiency virus type 1 (HIV-1) drug resistance is a significant clinical challenge.
- Multidrug-resistant (MDR) HIV-1 strains necessitate the development of novel antiviral agents.
- Nucleoside reverse transcriptase inhibitors (NRTIs) are a cornerstone of HIV-1 therapy.
Purpose of the Study:
- To evaluate the antiviral activity of 3 -fluoro-3 -deoxythymidine (FLT) against wild-type and MDR HIV-1 isolates.
- To compare the efficacy of FLT with AZT (azidothymidine) against various MDR HIV-1 mutants.
- To assess the potential for resistance development to FLT in HIV-1.
Main Methods:
- Antiviral activity determined by drug susceptibility assays and p24 antigen measurement via ELISA.
- Cytotoxicity of FLT and AZT assessed in peripheral blood mononuclear cells (PBMCs).
- Resistance development to FLT studied through serial passage of HIV-1 isolates under drug pressure.
Main Results:
- MDR HIV-1 isolates showed 7-fold to >100-fold increased resistance to AZT.
- FLT exhibited low IC(50) values (0.0014–0.0168 μM) against MDR isolates, comparable to wild-type (0.0075 μM).
- Resistance to FLT appeared to develop slower than for other reverse transcriptase inhibitors; MDR isolates showed no resistance to FLT.
Conclusions:
- FLT demonstrates potent activity against a range of MDR HIV-1 isolates.
- FLT may be a valuable option for salvage therapy in patients with treatment-experienced, resistant HIV-1 strains.
- Reassessment of FLT's therapeutic potential is warranted given its activity against resistant HIV-1.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...